版主:黑木崖
    
 · 九阳全新免清洗型豆浆机 全美最低
 
美国生物制药公司 VaxInnate
送交者: 居有肉和竹 2009月04月28日14:40:53 于 [世界军事论坛] 发送悄悄话
回  答: 4周内出疫苗---which company? helmsman 于 2009-04-28 14:33:05
if you google, tons of relative news....



WSJ Blogs

Search Venture Capital Dispatch
Venture Capital Dispatch
An inside look from VentureWire at high-tech start-ups and their investors.
  • April 27, 2009, 3:23 PM ET

Start-Ups Rush To Prep Swine-Flu Vaccine

By Brian Gormley

Venture-backed start-ups are readying swine-flu vaccines in case the recent outbreak escalates into a larger emergency.

The Department of Health and Human Services declared an emergency Sunday after 20 swine influenza A-virus infections were confirmed in the U.S., including eight in New York City and seven in California. U.S. cases have been mild, but some biotech start-ups are set to respond if officials decide existing vaccines aren’t enough.

swine2_D_20090427153438.jpg

Over the weekend, Vaxart Inc. secured the gene sequence for the swine-flu virus from the Centers for Disease Control and Prevention, said Sean Tucker, vice president of research for the San Francisco company, whose investors include Bay Partners and Quantum Technology Partners. The DNA sequence, pulled from a CDC database, will enable Vaxart to begin developing a vaccine that it will be ready to test in animals in four to six weeks.

The CDC said Sunday that it is working with the Food and Drug Administration and the National Institutes of Health to develop a vaccine precursor that could be used to make a swine-flu vaccine. The antigens that trigger a protective immune response in today’s vaccines, however, are grown in eggs over a period of six months or more. If the swine flu spreads rapidly, the government may turn to companies whose experimental technologies promise to yield large batches of vaccines more quickly. This could put start-ups like Vaxart in line to lock up lucrative contracts to supplement the government’s store of vaccines.

Vaxart makes vaccines by combining an antigen – in this case, the swine-flu DNA –  with a non-replicating viral vector and an adjuvant that boosts the immune response. This “modular” approach is about two months faster than egg or cell-culture systems, said Chief Executive Mark Backer. If swine flu becomes a large problem, U.S. regulators may permit Vaxart and others to move rapidly from animal research to human studies, he said.

Vaxart, which is also developing seasonal and avian-flu vaccines, may slow or suspend those programs if the swine flu affords it an opportunity to move its products more rapidly into human studies, Backer said.

Another company taking aim at seasonal and avian flu, VaxInnate Corp., plans to use the spate of swine-flu infections to see how rapidly it can come up with a vaccine candidate, said CEO Alan R. Shaw. The company, funded by CHL Medical Partners, HealthCare Ventures, and others, uses molecular biology to produce vaccines in e. coli instead of eggs or cell culture, which enables it produce a product in about six weeks. VaxInnate, based in Cranbury, N.J., already has tested a vaccine in clinical trials for Solomon Islands flu, which is similar to the swine flu, Shaw said.

While swine flu may be quickly contained, the government will need speedier vaccine-production technologies to manage future influenza outbreaks. “They’re going to need a tool like this sooner or later,” Shaw said. “This will happen over and over, it’s just a matter of how frequently.” 

Not all venture-funded concerns are jumping at swine flu. Vaxin Inc., a Birmingham, Ala., company funded by Greer Capital Advisors, and others, will not shift course to target what so far has been manageable problem in the U.S., said CEO William Enright. Instead, Enright intends to continue to concentrate on its intra-nasal vaccines for two more-established threats: seasonal and avian flu, he said.

“Vaxin is a pretty small company,” Enright said. “We need to stay focused on moving toward the marketplace.”


“John from Pennsylvania is on the line. Hello, John, welcome to QVC,” says a salesman on shopping channel QVC.

John goes on to explain the horrors of a computer crash and how excited he is to find a product that will easily back up his files. He’s ready to plop down $128.82, the “special” QVC price.

Not only is John from Pennsylvania excited, the salesmen are working themselves into a sweat hawking the Clickfree 160 gigabyte external hard drive. One of the salesmen even says, “We are excited as all get-out about this item.”

The maker of this product, Storage Appliance Corp., couldn’t have asked for better promotion as a young start-up. Reaching tens of millions of viewers, Storage Appliance, which does business as Clickfree, sold tens of thousands of units in about an hour and a half, Chief Executive Bryan McLeod said. That appearance (see video below) pushed the company to profitability nine months after it began shipping its first product in April 2008. “We went from zero sales to running at $4 million a month,” he said.

While the Clickfree products are available in retail stores such as Best Buy, OfficeMax and Walgreens, McLeod is a big believer in television shopping and has worked to get the product placed on shopping channels in Germany and the Middle East. “We’ve gotten so much air time, it’s the best marketing we could ask for,” McLeod said.

The key to Cickfree’s products - and their success on TV - is simplicity in both explanation and use. The company’s Web site boasts Clickfree is easier to use than toast. Simply connect the device to a computer and Clickfree will automatically find, organize, and back up all of your important data, it says. “It has to be totally effortless to get people to back up their computer,” McLeod said.

McLeod said the entire lineup of Clickfree products are designed for the 85% to 95% of computer users who, research shows, fail to regularly back up content on their PCs because they do not have the time, desire or skill to install, set up and use confusing or complex software and hardware products.

Thanks in part to its success on QVC, Storage Appliance linked up with a VC, announcing today that Toronto-based firm Jefferson Partners led a $10 million Series B funding for the Canadian company.

For guidance on how to get a product on QVC, check out the instructions on QVC’s Web site or tips from StartupNation.com.

0%(0)
0%(0)
  test in animals in 4--6weeks-- - helmsman 04/28/09 (484)
    Do you really know antibody?? - 居有肉和竹 04/28/09 (501)
        和那个hetero有得一比,知道一点就牛得不得了了.  /无内容 - rational 04/28/09 (453)
            最可笑的是牛得不知所以然.道不出了外国这么牛的原因出来 - rational 04/28/09 (502)
      hahaha, ur knowledge about Abs - helmsman 04/28/09 (489)
        I have done a couple of NIH - 居有肉和竹 04/28/09 (494)
          since u r working on Influenza - helmsman 04/28/09 (536)
            Wait 4~6 weeks is a good way f - 居有肉和竹 04/28/09 (515)
标 题 (必选项):
内 容 (选填项):
实用资讯
北美最大最全的折扣机票网站
美国名厂保健品一级代理,花旗参,维他命,鱼油,卵磷脂,30天退货保证.买百免邮.


一周点击热帖 更多>>
一周回复热帖